We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
EVRYSDI (Roche Products Pty Ltd)
Product name
EVRYSDI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
145 (255 working days)
Active ingredients
risdiplam
Registration type
NCE/NBE
Indication
EVRYSDI (powder for oral solution) is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients aged 2 months and older.
Registration process
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.